Nos complace anunciar el retorno a una reunión totalmente en persona, durante el Congreso Mundial 2024 de la FMH, el cual se realizará del 21 al 24 de abril, en Madrid, España. El congreso será el evento internacional más completo sobre trastornos de la coagulación, de modo que, si fuera usted una persona con un trastorno de la coagulación o su familiar, profesional de la salud, investigador, legislador, defensor de pacientes o miembro de la industria, ¡el Congreso Mundial 2024 de la FMH es un evento que no querrá perderse!
Congreso Mundial 2024 de la FMH
[email protected]
ORGANIZADOR:
Federación Mundial de Hemofilia
ANFITRIÓN:
Federación Española de Hemofilia
Al asistir al Congreso Mundial 2024 de la FMH, usted contribuirá a que la FMH continue ofreciendo programas y eventos esenciales para nuestra comunidad, particularmente en países con recursos limitados. El congreso ofrece a los participantes un foro para compartir conocimientos e instrucción, fomentar la colaboración, y ampliar su red de contactos. Constituye asimismo una oportunidad para que los líderes de la FMH se reúnan con representantes de diversos países a fin de abordar actividades de desarrollo.
Participarán en el congreso personas de todas las especialidades e intereses, entre ellas pacientes, hematólogos, pediatras, cirujanos ortopédicos, fisiatras, fisioterapeutas, dentistas, profesionales de enfermería, trabajadores sociales, psicólogos, genetistas, técnicos de laboratorio, investigadores, científicos, encargados de políticas, legisladores, defensores de pacientes y representantes de la industria.
Los asistentes al congreso podrán disfrutar de un programa de excelente calidad que abarcará los avances médicos y multidisciplinarios más recientes. Asimismo, el congreso contará con seis segmentos de sesiones profesionales en los campos de odontología, ciencias de laboratorio, cuidados musculoesqueléticos, atención psicosocial, enfermería y mujeres y niñas con trastornos hemorrágicos. También se abordarán los avances de los programas de la FMH, entre ellos el Registro Mundial de Trastornos de la Coagulación (RMTC), el Registro de Terapia Génica (RTG), la Iniciativa Piedra Angular, la Iniciativa sobre la EVW, el Programa de la FMH sobre acceso a atención y tratamiento (PACT por su sigla en inglés), y el Programa de hermanamiento. Además, por supuesto, una nutrida agenda social ayudará a los participantes a aprovechar al máximo su estancia en Madrid.
¡Siga leyendo para descubrir más acerca del Congreso Mundial 2024 de la FMH!
Desde 1965, el Congreso Mundial de la FMH se ha realizado cada dos años. Este importante evento contribuye al logro de nuestra misión de mejorar y preservar la atención para personas con trastornos de la coagulación hereditarios en todo el mundo.
La Asamblea General de la FMH es la encargada de tomar la decisión final relativa a la selección de la ciudad anfitriona del Congreso Mundial de la FMH. La selección de la ciudad anfitriona es un proceso abierto que apoya la misión de la FMH de atender a todos sus miembros, independientemente de su ubicación geográfica. Para cumplir este mandato, el congreso se realiza en una región diferente cada dos años.
El Recinto Ferial de IFEMA MADRID es una instalación de primera clase, de 200,000 m², con 13 pabellones, 85 salones, dos centros de convenciones y varias áreas al aire libre. El Centro de Convenciones Norte cuenta con un auditorio para 1,100 personas y con 18 salones adicionales, mientras que el Centro de Convenciones Sur ofrece otro auditorio con capacidad para 600 personas. Hay también 45 salones pequeños ubicados en el mezanine de los pabellones y dos pasarelas.
El Congreso Mundial 2024 de la FMH toma medidas como las siguientes a fin de garantizar que resulte un evento sustentable:
Comités
Personal de la FMH
Mostrar todos
Senior Director, Operations, WFH
Senior Manager, Exhibitions & Special Events, WFH
CEO, WFH
Vice-President, Finance, WFH
Presidente, Federación Española de Hemofilia (Fedhemo) - host NMO
WFH President
Secretario General, Fedhemo
Manager, Fedhemo
Vicepresidenta 1°, Fedhemo
Manager, Scientific Program, WFH
Director, Congress & Meetings, WFH
Mr. Antonio José Almeida is the Senior Director of Operations at the World Federation of Hemophilia (WFH) in Montreal, Canada. He oversees and guides all key WFH general operation functions – Congress & Meetings, Finance & Administration, Information Technology, and Human Resources.
Previously, from March 2016 to June 2019 he was Director of Programs and Education and responsible for the planning, implementation, follow-up and evaluation of international health care development programs, as well as the delivery of medical education, training curricula, and the development of educational resources. He also supported the CEO in his work with corporate partners. From October 2008 to March 2016 he was Director of Programs and was also responsible for all WFH country programs, the Global Alliance for Progress (GAP) and Cornerstone Initiative programs.
Danielle is a seasoned Senior Congress and Meetings Manager with over 20 years of experience in the international meeting planning industry. With a proven track record of success, Danielle has developed strong communication skills and an ability to solve practical problems while thriving in a lively but pressured environment.
Her specialties include exhibit and sponsorship sales, floor plan development, virtual conferences, meeting logistics, project management, budget management, supplier selection and site inspections.
Danielle previously worked at the International Air Transport Association (IATA) in their events department, where she gained invaluable experience working with a high-profile organization in the industry.
With her extensive experience and unique skill set, Danielle is a valuable asset to any organization looking to execute successful and impactful events.
Alain Baumann is the CEO of the World Federation of Hemophilia (WFH) and has held this position since 2015. Alain brings with him a proven track record leading non-profit as well as for-profit healthcare organizations. Early on in his career, he worked for a major pharmaceutical company holding marketing and general manager positions. Within the non-profit sector he worked for the World Economic Forum as well as for the AO Foundation, a global non-profit organization focusing on education and research in orthopedic surgery.
Barry Flynn has been Vice-President, Medical, for the WFH since 2018. A father of three, Flynn was born with severe hemophilia A. He graduated with first class honours degree in Biochemistry from Liverpool University, became a Chartered Accountant (CA) soon thereafter and then completed an MBA with distinction from IMC in 1991. Flynn was an audit partner for EY for 21 years until his retirement in 2015. He is a qualified executive coach and mentor, and currently has non-executive director roles at the WFH, with Liverpool University, the UK Haemophilia Society and the Manchester Growth Company.
Licenciado en Derecho por la Universidad de Cantabria y abogado en ejercicio del Ilustre Colegio de Abogados de Madrid, Daniel-Aníbal Garcia Diego es Máster en Análisis Económico del Derecho y de las Políticas Públicas por el Instituto Ortega y Gasset-UCM y Máster de Gestión y Planificación Sanitaria para Directivos de la Salud por la UEM-SEDISA.
Autor de diversas comunicaciones científicas en diferentes congresos nacionales e internacionales del sector de la hematología, la hemostasia y la economía de la salud, ha participado como ponente en numerosas reuniones científicas. Además de ser socio de sociedades científicas relacionadas con la salud y la gestión sanitaria, es Becario "Youth Fellow" por la World Federation of Hemophilia.
Vinculado al movimiento asociativo desde 2004, año en el que comenzó a formar parte como miembro activo de la Asociación Cántabra de Hemofilia, ha ocupado diversos cargos dentro de la Comisión Permanente de Fedhemo, siendo Presidente desde abril de 2015.
Desde 2016 es Secretario de Organización de COCEMFE Nacional y desde 2018 es también Presidente de FEACEM.
Cesar Garrido was born in Caracas, Venezuela. He has two sons, one of whom has hemophilia A, which was the impetus for him becoming a committed member of the bleeding disorders community—a commitment which began over two decades ago.
In 1996, Garrido became a member of the Venezuelan Association for Hemophilia (AVH). He has held a number of roles in that organization, including being a member of the Board of Directors and Treasurer and Project Manager. At the AVH, he has been key member of several endeavours, including the creation of new diagnostic laboratories in Venezuela, and campaigns for testing and diagnosis of people with hemophilia (PWH) in Venezuela and Latin America. He was also part of national programs which increased access to factor, developed outreach and identification campaigns, increased access to education, and set up regional medical workshops for PWH.
At the international level, Garrido was an Advisory Board member of the International Alliance Patient Organization (IAPO) and has been a member of HERO (Haemophilia Experiences, Results and Opportunities) since 2010. He was also a development manager for a strategic alliance of 27 countries from the Americas—called the Coalition of the Americas (CoA)— that was set up to influence public policies.
The WFH has been a big part of Cesar Garrido’s life since 1999. He was a member of the Board of Directors from 2002 to 2010 and was most recently lay member from 2014 until his election as President in 2020. He has held a number of important roles at the WFH, including chair of the Accreditation Committee, chair of the Hemophilia Organization Twinnings (HOT) Committee, co-chair of Capacity Building Committee, national member organization (NMO) Vice President, and member of the President’s Strategic Council.
Desarrolla una labor vinculada al mundo asociativo y de la discapacidad desde 2001, año en el que empezó a formar parte de la Junta Directiva de la Asociación Malagueña de Hemofilia (AMH). En marzo de 2011 fue elegido Presidente de la asociación. Durante este periodo se consiguieron muchos avances a nivel de coordinación con el Departamento de Hematología del Hospital Regional Universitario de Málaga y se fomentó la implicación de los miembros de la Junta Directiva, trabajadores, voluntarios y socios. En la actualidad es vicepresidente.
Durante 2012 formó parte de la comisión de discapacitados orgánicos de COCEMFE Málaga como coordinador. Es presidente de Málaga Inclusiva COCEMFE, Presidente de la Asociación de personas con Hemofilia y otras coagulopatías congénitas de Andalucía (ASPHA) y miembro del Consejo sectorial de Accesibilidad y del Consejo Sectorial de Bienestar Social del Ayuntamiento de Málaga.
Desde abril de 2014 ocupa el cargo de Secretario General de la Federación Española de Hemofilia.
Diplomada en Trabajo Social por la Universidad de Salamanca; Post grado en RRHH por EAE Business School; Titulada Superior en Dirección de ONG y Experta en Gestión Asociaciones de Pacientes por la UNED. Trabajadora social Sanitaria con más de 16 años de experiencia en el movimiento asociativo, dedicada a la intervención social con casos grupos y comunidades.
Desde hace 10 años centrada en la dirección, gestión, incidencia política, coordinación y mediación con administraciones públicas en defensa de los derechos del paciente, actualmente ejerce como directora gerente en la Federación Española de Hemofilia.
Colabora con la Asociación Española de Trabajo Social y Salud de Madrid (AETSyS) y forma parte de la Comisión de Trabajo Social Sanitario del Colegio Oficial de Trabajadores Sociales de Madrid desde el 2021.
Participa como docente en programas formativos de la Universidad autónoma de Madrid, la Universidad complutense de Madrid y Fundación Humans. Profesora adjunta en el Máster de Trabajo social Sanitario de la Universidad de Comillas, Madrid.
Autora principal y coatura de artículos, guías para profesionales del tercer sector, estudios e investigaciones publicadas a nivel nacional e internacional relacionados con la importancia de las asociaciones de pacientes, discapacidad, ejercicio del trabajo social e impacto de la Covid 19 en enfermos crónicos.
Estudios de Economía. Trabajó en la Asociación Gallega de Hemofilia (AGADHEMO) desde 2009 hasta 2013 como coordinadora de proyectos. Desde 2013 trabaja en Combina Social, S.L., como técnica de proyectos.
Forma parte de la Junta Directiva de AGADHEMO desde 2004 como Vocal, posteriormente como Tesorera y actualmente como Presidenta. Forma parte la Junta Directiva de COGAMI desde el año 2011. Es miembro de la Junta Directiva de la Federación de Ourense DISCAFIS- COGAMI desde el año 2005 y Presidenta de la misma desde el año 2012. También es socia fundadora y componente de la Junta Directiva de la Asociación de Mujeres con Discapacidad (ACADAR) desde 2009.
En septiembre de 2017 se incorpora a la Comisión Permanente de Fedhemo como Vocal donde actualmente ocupa el cargo de vicepresidenta.
¡Más información en breve!
Jeremias Rodriguez is a seasoned Meeting Planner Executive with over 20 years’ experience in leading, planning and executing Virtual and In-person Events, domestically and internationally, across a variety of businesses including Associations, PCOs and DMCs.
Jeremias leads the Congress and Meetings department at the World Federation of Hemophilia (WFH) where he provides organization-wide leadership, strategic guidance and direction relating to the effective planning and execution of WFH events, in-person and virtual, as well as other educational and informational meetings world-wide.
Previous to the WFH, Jeremias worked at the International Airports Association where he ran the Events department and he had previously held various management roles at leading Canadian, US and Mexican PCOs and DMCs including Tropical Incentives, Terramar Destinations, Amstar-Apple Vacations and Altima Concept.
© 2025 World Federation of Hemophilia
Registro caritativo: 108222050 RR 0001
The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.
The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.
Recognizing that training women leaders ensures the diversity our community need to thrive; the Hemophilia Alliance has been a longtime supporter of the Susan Skinner Memorial Fund. They deepened their engagement with the global community through the establishment of the Travel Grant Program, which allows US-based multidisciplinary healthcare professionals the opportunity to attend WFH global training workshops. The wealth of experience and perspective attendees bring back home to their communities helps patients across the country. Their patience and support as we grappled with changing norms in these challenging times gave us the flexibility to meet our community’s needs with revamped programming.
Hemophilia of Georgia has stood with us for over three decades, playing an early role in distributing donated factor via the WFH Humanitarian Aid program. Our relationship has deepened over the years as they continued to support this program and came on board as a founding Chapter Challenge champion in 2016. Their belief in educating future leaders is clear in their investment in the Youth Leadership Workshops, which has led to the training of over 50 young adults. They also support workshops devoted to educating providers and patient leaders on how to collect and use data to advocate for better patient care. Their staff generously volunteer their time as trainers and as well as serving on various committees.
The National Bleeding Disorders Foundation helps advance our mission on several fronts. They inspire others to follow their lead as a founding champion of the NHF Chapter Challenge. Their commitment to equality of access is demonstrated in their support of the Cornerstone Initiative, which lays the foundation for care in the world's most underserved regions, as well as programs that aim to raise awareness and improve care of women with bleeding disorders and those with von Willebrand disease. We also benefit from their steadfast engagement with various programs including the WFH Twinning Program and their individual leaders’ contribution to our leadership and committees.
Do you sometimes wish you could do more? A bequest is a simple way for you to make a significant gift without changing anything about your financial security and lifestyle today. Your legacy will sustain care for the generations to come.
Download these sample clauses to give to your legal advisor.
We understand if you prefer to remain anonymous, but we would be very honoured if you would let us know of your intentions so that we may thank you personally. We would also be happy to answer any questions you may have or give you additional information. Please contact Jennifer Laliberté at 514‑875‑7944 ext.2822 or [email protected].
The information on the WFH USA website is provided for general information purposes only. The WFH USA does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH USA recommends that you contact your physician or local treatment centre. Before administering any products, the WFH USA urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH USA does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH USA discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH USA social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH USA recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH USA. The WFH USA is not responsible and assumes no liability for the content of any linked websites.
The WFH USA does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.
Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH USA, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH USA or the use of its logo needs to be approved by the WFH USA. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”
All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH USA. To view a copy of the WFH USA’s permissions guidelines, click here.
The WFH USA encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].
If you have suggestions on how to make the site more accessible, please contact us at [email protected].
Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].
The WFH USA has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH USA staff or falsely stating that they are associated with the WFH USA. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH USA, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH USA emails come from @wfhusa.org or @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH USA at [email protected] or call 1-877-417-7944.
| 2012 | Piet de Kleijn Países Bajos |
| 2010 | Dr. Mammen Chandy India |
| 2008 | Dr. Man-Chiu Poon Canadá |
| 2006 | Dr. Norma de Bosch Venezuela |
| 2004 | Dr. Parttraporn Insarangkura Tailandia Dr. Carol K. Kasper Estados Unidos |
| 2022 | Ammán (Jordania) – Dublín (Irlanda) |
| 2021 | Addis Abeba (Etiopía) – Minneapolis (EE.UU.) y Teherán (Irán) – Milán (Italia) |
| 2020 | Aluva (India) – Newcastle (Reino Unido) |
| 2019 | Yogyakarta / Solo (Indonesia) – Utrecht (Países Bajos) |
| 2018 | Abidjan (Costa de Marfil) – Bruselas (Bélgica) |
| 2017 | Santa Cruz de la Sierra (Bolivia) – Buenos Aires (Argentina) |
| 2016 | Kampala (Uganda) – Londres (Reino Unido) |
| 2015 | Varna (Bulgaria) – Bonn (Alemania) |
| 2014 | Arequipa (Perú) – Los Ángeles (Estados Unidos) |
| 2013 | Davangere (India) – Liverpool (Reino Unido) Ludhiana (India) – Detroit (Estados Unidos) |
| 2012 | Hanói (Vietnam) – Melbourne (Australia) |
| 2011 | Manado (Indonesia) – Utrecht (Países Bajos) |
| 2010 | Delhi (India) – Winnipeg (Canadá) Yaoundé (Camerún) – Ginebra (Suiza) |
| 2009 | Chisinau (Moldovia) – Varsovia (Polonia) Colombo (Sri Lanka) – Vellore (India) |
| 2008 | Gaborone (Botswana) – Filadelfia (Estados Unidos) |
| 2007 | Vientiane (Laos) – Brest (Francia) Damasco (Siria) – Montpellier (Francia) |
| 2006 | Lima (Perú) – Fort Worth (Estados Unidos) |
| 2005 | Ereván (Armenia) – Minneapolis (Estados Unidos) Casablanca (Marruecos) – Caen (Francia) |
| 2004 | Beirut (Líbano) – Ginebra (Suiza) Santo Domingo (República Dominicana) – Caracas (Venezuela) |
| 2003 | El Cairo (Egipto) – Knoxville (Estados Unidos) |
| 2002 | Moscú (Rusia) – Liverpool (Reino Unido) Panamá – Valencia (España) |
| 2001 | Bangalore (India) – St. Louis (Estados Unidos) |
| 2000 | Pune (India) – Bradford (Reino Unido) |
| 1999 | Montevideo (Uruguay) – Buenos Aires (Argentina) Tianjin (China) – Calgary (Canadá) |
| 1998 | Plovdiv (Bulgaria) – Bonn (Alemania) |
| 1997 | Bogotá (Colombia) – Los Ángeles (Estados Unidos) Tartu (Estonia) – Estocolmo (Suecia) |
| 1996 | Timisoara (Rumanía) – Múnich (Alemania) Riga (Letonia) – Munster (Alemania) |
| 1995 | Klaipeda (Lituania) – Malmo (Suecia) |
| 1994 | Bratislava (Eslovaquia) – Tel Hashomer (Israel) |
| 2025 | Greig Blamey Canadá |
| 2023 | Nicholas Goddard Reino Unido |
| 2021 | Axel Seuser Alemania |
| 2019 | Dr. Adolfo Llinás Colombia |
| 2017 | Pamela Hilliard Canadá |
| 2015 | Kathy Mulder Canadá |
| 2013 | James Luck Estados Unidos |
| 2012 | Piet de Kleijn Países Bajos |
| 2011 | Dr. Lily Heijnen Países Bajos |
| 2010 | Dr. Horacio Caviglia Argentina |
| 2009 | Jerome D. Wiedel Estados Unidos |
| 2008 | Dr. Federico Fernández-Palazzi Venezuela |
| 2007 | Michael Heim Israel |
| 2006 | Brenda Buzzard Reino Unido |
| 2005 | Dr. Marvin Gilbert Estados Unidos |
| 2025 | Shubhranshu S. Mohanty India |
Haemophilic pseudotumour – New improvised classification system and its outcome in 168 cases at a Tertiary care centre |
| 2021 | Baolai Hua China |
The effects of intra-articular injection of TNF-alpha Antagonists in treatment of haemophilic synovitis |
| 2019 | Maarten Eerdekens Bélgica |
Asociación entre la cinética multisegmento del pie y el daño articular inducido por la sangre en pacientes adultos con artropatía hemofílica del tobillo |
| 2017 | Fabio Souza Brasil |
Decrease in joint inflammation, swelling and pain after a swimming protocol in animal model of experimental-induced hemarthrosis |
| 2015 | SM Javd Mortazavi Irán |
Bilateral total knee arthroplasty in patients with hemophilia: A safe and cost-effective procedure |
| 2013 | Lize F.D. van Vulpen Estados Unidos |
Una proteína de fusión de IL4 e IL10 es igualmente eficaz para proteger el cartílago del daño inducido por la sangre en comparación con los componentes |
| 2012 | Horacio Caviglia Argentina |
Cirugía de pseudotumor en pacientes con hemofilia A: resultados comparativos entre pacientes inhibidores y no inhibidores |
| 2011 | Nick Goddard Reino Unido y Monique van Meegeren Países Bajos |
La administración temprana de IL-4 e IL-10 previene el daño del cartílago inducido por la sangre in vitro |
| 2010 | Lydia Abad-Franch España |
Influencia de un protocolo de entrenamiento acuático en la reducción del riesgo de morbilidad y mortalidad cardiovascular en un hemofílico |
| 2009 | Sebastien Lobet Bélgica |
Impacto de la artropatía del tobillo con hemofilia en la discapacidad de la marcha: análisis de variables energéticas y mecánicas |
| 2008 | Jose Alberto Tlacuilo-Parra México |
Marcadores de rotación ósea y densidad mineral ósea en niños con hemofilia |
| 2007 | Natalie Jansen Países Bajos |
Capacidades protectoras de la interleucina-10 en el daño del cartílago inducido por la sangre |
| 2006 | Axel Seuser y E. Kusch Alemania |
Estudio multicéntrico del resultado ortopédico de las extremidades inferiores en 249 niños con hemofilia |
| 2005 | Frank van Genderen, Nico van Meeteren, Lily Heijnen, Piet de Kleijn, Marijke van den Berg, Paul Helders Países Bajos |
Lista de actividades para la hemofilia: desarrollo final y validación de un cuestionario de autoevaluación específico para hemofilia sobre las capacidades funcionales |
| 2004 | Goris Roosendaal, Zalima N Jahangier, Kim MG Jacobs, Johannes WJ Bijlsma, Floris PJG Lafeber Países Bajos |
La radiosinoviortesis con YTTRIUM-90 da como resultado efectos directos adversos sobre el cartílago: un estudio in vitro en humanos |
| 2003 | Axel Seuser, Thomas Wallny, Günter Schumpe, Elmar Trunz, Hans-Hermann Brackman Alemania |
¿Cómo aconsejar a los jóvenes hemofílicos que encuentren el deporte adecuado? Un algoritmo nuevo y seguro |
| 2002 | James Luck, Jr. y Mauricio Silva Estados Unidos |
Revisión a largo plazo de la artroplastia total de rodilla |
| 2001 | Federico Fernández-Palazzi Venezuela |
Clorhidrato de oxitetraciclina: un nuevo material para las órtesis sinoviales químicas |
| 2000 | Horacio Caviglia Argentina |
Pseudotumores |
| 1999 | William J. Ribbans y J.L. Hicks Reino Unido |
Comunicación y cooperación para el nuevo milenio: el futuro del comité musculoesquelético en el siglo XXI |
| 1998 | Adolfo Llinas, Mauricio Silva, Monica Duarte, Gonzalo Ucros, Graciela Perini, Angela Maria Cerquera, Andres Forero Colombia |
La sinoviortesis de fosfato crómico sin restricción de edad debería ser la primera opción de tratamiento para la sinovitis hemofílica activa crónica |
Los resultados de interés recolectados en el RMTC abarcan características demográficas, resultados médicos y relacionados con el tratamiento, resultados de la carga de la enfermedad, y resultados reportados por los pacientes.
El RMTC incluye cinco escalas funcionales (en inglés) como parte de su conjunto de datos ampliados:
El conjunto de datos mínimo (CDM) es un grupo de datos demográficos, sobre diagnóstico, síntomas y tratamiento que se recolecta de los pacientes que participan en el RMTC.
El conjunto de datos ampliado (CDA)es un grupo de datos más grande, con mayores detalles que el CDM, que abarca preguntas sobre datos demográficos, diagnóstico, síntomas, tratamiento y carga de la enfermedad de los pacientes. Los centros de tratamiento de hemofilia pueden utilizar el CDA para recolectar información de pacientes que participan en el RMTC. El conjunto de datos ampliado (CDA) del RMTC se agregó a la base de datos en marzo del 2019.
Nationwide Children’s Hospital
Gulf States Hemophilia and Thrombophilia Center
University of Texas Health Science Center at Houston
Lifespan Orthopaedic Hemophilia Treatment Center at Luskin Orthopedic Institute for Children
Mount Sinai School of Medicine
Mount Sinai Medical Center
Mayo (Rochester) Comprehensive Hemophilia Center, and International Hemophilia Training Center (WFH)
Mayo Clinic/Foundation and Mayo Medical School
Hemophilia & Thrombosis Treatment Center
University of California San Diego
Katharine Dormandy Haemophilia Centre and Thrombosis Unit
Royal Free Hospital
Oxford Haemophilia and Thrombosis Centre
Churchill Hospital
Sheffield Haemophilia and Thrombosis Centre
Royal Hallamshire Hospital
International Hemophilia Training Center – Bangkok
Ramathibodi Hospital
Mahidol University
Malmö Centre for Thrombosis and Haemostasis
Department for Hematology and Coagulation Disorders, Skåne University Hospital
Skåne University Hospital
Hospital Universitario La Paz
Haemostasis and Thrombosis Unit
Haematology Service, University and Polytechnic Hospital
Haemophilia Comprehensive Care Centre
Charlotte Maxeke Johannesburg Academic Hospital
Singapore General Hospital Haemophilia Treatment Clinic
Centre International de Traitement de l’Hémophilie (CITH) de Dakar
Centre National de Transfusion Sanguin (CNTS)
National Medical Research Center of Hematology of the Russian Academy of Medical Sciences
Van Creveldkliniek
University Medical Centre Utrecht
Nara Hemophilia Centre
Nara Medical University
Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
National Hemophilia Center, Tel Hashomer
Sheba Medical Center
National Institute of Immunohaematology (ICMR) and KEM Hospital
Christian Medical College, Vellore
Paris Haemophilia Centre (Necker (N) and Kremlin Bicêtre (KB) Hospitals)
Shabrawishi Hospital, Egyptian Society of Hemophilia, and Cairo University
University of Toronto Hemophilia Centres
St. Michael’s Hospital
Hemocentro – “Unidade de Hemofilia Cláudio Luiz Pizzigatti Corrêa”
Hemocentro Unicamp, University of Campinas
Haemostasis and Thrombosis Unit
Division of Haematology
Cliniques universitaires Saint-Luc
Medical University of Vienna
Department of Medicine I
Clinical Division of Hematology and Hemostaseology
Ronald Sawers Haemophilia Treatment Centre
Instituto Asistencial “Dr. Alfredo Pavlovsky”
(Fundación de la Hemofilia)
Instituto De Investigaciones Hematológicas “Dr. Mariano R. Castex” (IIHEMA
(Academia Nacional de Medicina)
Frank Schnabel, un hombre de negocios canadiense con hemofilia A grave, fundó la FMH en 1963. Schnabel estaba convencido de que las organizaciones de pacientes podían ser mucho más eficaces, y hacer más para representar los intereses de las personas con trastornos de la coagulación, si trabajaban unidas. El primer Congreso de la FMH se realizó en Copenhague, Dinamarca, el 25 de junio de 1963, y en él participaron representantes de 12 países. Actualmente, la FMH y su red mundial de organizaciones nacionales miembros (ONM) representan los intereses de personas con hemofilia y otros trastornos de la coagulación hereditarios en 152 naciones.
Kit de herramientas de redes sociales del Congreso
Ayúdenos a crear expectación con nuestro kit de herramientas para redes sociales y pase la voz acerca del Congreso Mundial 2024 de la FMH. Unidos tenemos la capacidad de remodelar el futuro de los trastornos de la coagulación. ¡Comparta la emoción y difunda la noticia a todo el mundo!
Materiales del congreso
Encabezados
Imágenes de redes sociales 1200x627
Imágenes de redes sociales 1080x1080
Imágenes de redes sociales 1080x1920
Imágenes de redes sociales 1080x1920 (Animadas)
Encabezados
Imágenes de redes sociales 1200x627
Imágenes de redes sociales 1080x1080
Imágenes de redes sociales 1080x1920
Imágenes de redes sociales 1080x1920 (Animadas)
Encabezados
Imágenes de redes sociales 1200x627
Imágenes de redes sociales 1080x1080
Imágenes de redes sociales 1080x1920
Imágenes de redes sociales 1080x1920 (Animadas)